CZECRIN

CZEch
Clinical
Research
Infrastructure
Network

„...towards patient oriented medicine!“

Most likely, each of us has encountered a health condition in our daily lives in which he was forced to take a medicine. It could be a short-term drug administration for sore throat, cold or flu, other times. It is necessary to take the drug for a long time. The truth is that the route of a drug or the life cycle of a drug is not a matter of a few days. It is a process of many years of research, laboratory testing and clinical trials. For such a drug development and reaching the patient, it is necessary to ensure the adequate environment for research and development, scientific capacity, finance and legislative conditions. To register each drug, you need to overcome many drawbacks and overcome many barriers. Not just one individual, often not a single team will succeed. It is necessary to connect many different expertises, besides, sometimes small details are missing, yet you cannot move your research further. This is exactly where CZECRIN comes in.

CZECRIN is a large research infrastructure connecting research and clinical workplaces where non-commercial clinical research takes place by supporting non-commercial clinical studies. The goal of the CZECRIN infrastructure is to **increase the quality and number of non-commercially initiated clinical trials in the Czech Republic**, using available capacity and expertise of involved workplaces with a guarantee of compliance with regulatory, legislative and ethical requirements related to conducting clinical research. The connection to the European ECRIN and our initiative in further education further opens the door to the world of unintended science and research possibilities. We are fully aware of the value of education and thus place it on the top of the list of priorities. We, therefore, invest in the education of ourselves, but we also offer it to you. If you also need help with the implementation of your research, go to our expertise, and we will help you complete your research to the end.